Novartis, Pfizer join forces on potentially lucrative fatty liver disease

Novartis, Pfizer join forces on potentially lucrative fatty liver disease


Novartis AG and Pfizer Inc are teaming up to develop treatments for a liver disease many drug companies believe will become a hugely lucrative market, as it is tied to the obesity and diabetes epidemics. FILE PHOTO: Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017.



from Biotech News
Share:

Комментариев нет:

Отправить комментарий

Pharmacy News Digest

Архив блога